comparemela.com

Board Of Wolftank Adisa Holding News Today : Breaking News, Live Updates & Top Stories | Vimarsana

21st Austria weekly - Wolftank, Zumtobel (07/12/2022)

21st Austria weekly - Wolftank Zumtobel 07/12/2022 [pic1]Wolftank: The Executive Board of Wolftank-Adisa Holding AG has decided to increase the share capital company by issuing up 438.093 new no-par value bearer shares at issue price Euro 14.01 per share. shareholders subscription rights be issued are excluded. According company serves strengthen equity base and finance current or planned projects. increased number inquiries in field refueling systems for renewable energies environmental remediation existing European infrastructure requires an accelerated positioning key markets such as Germany. This is supported strategic partnerships participations.Wolftank-Adisa: performance: 0.78% Zumtobel: lightning group following announcement preliminary numbers first half-year on 10 November

21st Austria weekly - Andritz, Marinomed, Valneva, Pierer Mobility, Palfinger, Wolftank Adisa (12/04/2021)

18.04.2021 Andritz: International technology Group Andritz has successfully started up a new 500 t/d Herb chemical recovery boiler at Kuantum Papers Limited in Saila Khurd, Hoshiapur district in the state of Punjab, India. The boiler is designed to handle a mixture of hardwood and agro-based black liquor and enables environmentally friendly and more energy-efficient operation compared to a conventional boiler with direct contact evaporator. Thus, the mill’s pulp production as well as the power-to-heat-ratio are substantially increased. The boiler also features a unique vertical air system to minimize air emissions. Andritz: weekly performance: -1.21% Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that out of the initially enrolled 64 patients, all 62 patients included in the treatment cycles have now concluded the Phase II clinical trial e

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.